SG11201701741QA - Methods and compositions for inducing protective immunity against filovirus infection - Google Patents
Methods and compositions for inducing protective immunity against filovirus infectionInfo
- Publication number
- SG11201701741QA SG11201701741QA SG11201701741QA SG11201701741QA SG11201701741QA SG 11201701741Q A SG11201701741Q A SG 11201701741QA SG 11201701741Q A SG11201701741Q A SG 11201701741QA SG 11201701741Q A SG11201701741Q A SG 11201701741QA SG 11201701741Q A SG11201701741Q A SG 11201701741QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- immunity against
- protective immunity
- inducing protective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045522P | 2014-09-03 | 2014-09-03 | |
| US201562116021P | 2015-02-13 | 2015-02-13 | |
| US201562189109P | 2015-07-06 | 2015-07-06 | |
| PCT/US2015/048357 WO2016036955A1 (en) | 2014-09-03 | 2015-09-03 | Methods and compositions for inducing protective immunity against filovirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701741QA true SG11201701741QA (en) | 2017-04-27 |
Family
ID=54186280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701741QA SG11201701741QA (en) | 2014-09-03 | 2015-09-03 | Methods and compositions for inducing protective immunity against filovirus infection |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10561721B2 (en) |
| EP (2) | EP3656395B1 (en) |
| JP (1) | JP6462861B2 (en) |
| KR (1) | KR101963985B1 (en) |
| CN (1) | CN107454848B (en) |
| AU (1) | AU2015311852B2 (en) |
| BR (1) | BR112017003891A2 (en) |
| CA (1) | CA2960092C (en) |
| DK (2) | DK3656395T3 (en) |
| EA (1) | EA035504B1 (en) |
| ES (1) | ES2777323T3 (en) |
| FI (1) | FI3656395T3 (en) |
| HR (2) | HRP20240163T1 (en) |
| HU (1) | HUE048318T2 (en) |
| IL (1) | IL250743B (en) |
| LT (2) | LT3188753T (en) |
| MX (1) | MX2017002889A (en) |
| MY (1) | MY183072A (en) |
| NZ (1) | NZ730511A (en) |
| PL (2) | PL3656395T3 (en) |
| PT (2) | PT3188753T (en) |
| SG (1) | SG11201701741QA (en) |
| SI (2) | SI3656395T1 (en) |
| UA (1) | UA125013C2 (en) |
| WO (1) | WO2016036955A1 (en) |
| ZA (1) | ZA201701815B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110072536B (en) * | 2016-05-05 | 2024-02-02 | 宾夕法尼亚大学理事会 | Filovirus consensus antigens, nucleic acid constructs, vaccines made therefrom, and methods of use thereof |
| US10925955B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a Marburg virus infection |
| EP3484507A1 (en) * | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| US20200289636A1 (en) * | 2017-09-07 | 2020-09-17 | Hawaii Biotech, Inc. | Filovirus vaccines and methods of use |
| JP7437385B2 (en) | 2018-09-06 | 2024-02-22 | バヴァリアン・ノルディック・アクティーゼルスカブ | Poxvirus composition with improved storage |
| KR20220153587A (en) | 2020-03-12 | 2022-11-18 | 버베리안 노딕 에이/에스 | Compositions to improve poxvirus stability |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| WO2000000616A2 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| WO2000008131A2 (en) * | 1998-08-04 | 2000-02-17 | Purdue Research Foundation | Pseudotyped retroviruses and stable cell lines for their production |
| ATE445018T1 (en) | 1999-05-17 | 2009-10-15 | Crucell Holland Bv | ADENOVIRUS-DERIVED GENE TRANSFER VEHICLES CONTAINING AT LEAST ONE ELEMENT OF ADENOVIRUS TYPE 35 |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| AU2002231639B2 (en) | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| EP1450854A2 (en) | 2001-11-30 | 2004-09-01 | Isis Innovation Limited | Vaccine |
| AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| PT1497438E (en) | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors |
| ATE405663T1 (en) | 2002-04-25 | 2008-09-15 | Crucell Holland Bv | STABLE ADENOVIRAL VECTORS AND METHODS FOR THEIR PROPAGATION |
| PL2163260T3 (en) | 2004-01-23 | 2017-12-29 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
| JP5046941B2 (en) | 2004-09-27 | 2012-10-10 | アメリカ合衆国 | Vaccines optimized for protection against Ebola and other viruses |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| US8603468B2 (en) | 2007-11-06 | 2013-12-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Neutralization of HCV |
| CN106318978B (en) * | 2008-11-21 | 2020-06-23 | 巴法里安诺迪克有限公司 | Vector comprising multiple homologous nucleotide sequences |
| NZ594355A (en) | 2009-02-02 | 2012-11-30 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| NZ600629A (en) | 2010-01-28 | 2014-12-24 | Bavarian Nordic As | Vaccinia virus mutants containing the major genomic deletions of mva |
| TR201902214T4 (en) | 2010-04-16 | 2019-03-21 | Glaxosmithkline Biologicals Sa | Chimpanzee adenoviral vector-based filovirus vaccines. |
| ES2676196T3 (en) * | 2010-12-14 | 2018-07-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines against adenovirus filovirus serotype 25 and serotype 35 |
| EP2670843B1 (en) * | 2011-02-03 | 2014-10-29 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Multivalent vaccines for rabies virus and filoviruses |
| KR102146904B1 (en) * | 2012-04-12 | 2020-08-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| EP2892549A1 (en) | 2012-09-04 | 2015-07-15 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| GB201303406D0 (en) | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 HR HRP20240163TT patent/HRP20240163T1/en unknown
- 2015-09-03 FI FIEP19216773.2T patent/FI3656395T3/en active
- 2015-09-03 PT PT157676313T patent/PT3188753T/en unknown
- 2015-09-03 MX MX2017002889A patent/MX2017002889A/en unknown
- 2015-09-03 US US15/507,975 patent/US10561721B2/en active Active
- 2015-09-03 MY MYPI2017700699A patent/MY183072A/en unknown
- 2015-09-03 SI SI201531986T patent/SI3656395T1/en unknown
- 2015-09-03 PL PL19216773.2T patent/PL3656395T3/en unknown
- 2015-09-03 DK DK19216773.2T patent/DK3656395T3/en active
- 2015-09-03 PL PL15767631T patent/PL3188753T3/en unknown
- 2015-09-03 SG SG11201701741QA patent/SG11201701741QA/en unknown
- 2015-09-03 EP EP19216773.2A patent/EP3656395B1/en active Active
- 2015-09-03 HU HUE15767631A patent/HUE048318T2/en unknown
- 2015-09-03 PT PT192167732T patent/PT3656395T/en unknown
- 2015-09-03 UA UAA201703034A patent/UA125013C2/en unknown
- 2015-09-03 WO PCT/US2015/048357 patent/WO2016036955A1/en active Application Filing
- 2015-09-03 BR BR112017003891A patent/BR112017003891A2/en not_active Application Discontinuation
- 2015-09-03 JP JP2017512990A patent/JP6462861B2/en active Active
- 2015-09-03 DK DK15767631.3T patent/DK3188753T3/en active
- 2015-09-03 CA CA2960092A patent/CA2960092C/en active Active
- 2015-09-03 NZ NZ730511A patent/NZ730511A/en unknown
- 2015-09-03 AU AU2015311852A patent/AU2015311852B2/en active Active
- 2015-09-03 ES ES15767631T patent/ES2777323T3/en active Active
- 2015-09-03 IL IL250743A patent/IL250743B/en unknown
- 2015-09-03 KR KR1020177008911A patent/KR101963985B1/en active IP Right Grant
- 2015-09-03 CN CN201580047578.5A patent/CN107454848B/en active Active
- 2015-09-03 EP EP15767631.3A patent/EP3188753B1/en active Active
- 2015-09-03 EA EA201790517A patent/EA035504B1/en unknown
- 2015-09-03 LT LTEP15767631.3T patent/LT3188753T/en unknown
- 2015-09-03 LT LTEP19216773.2T patent/LT3656395T/en unknown
- 2015-09-03 SI SI201531108T patent/SI3188753T1/en unknown
-
2017
- 2017-03-14 ZA ZA2017/01815A patent/ZA201701815B/en unknown
-
2019
- 2019-10-17 US US16/655,516 patent/US11173201B2/en active Active
-
2020
- 2020-02-19 HR HRP20200285TT patent/HRP20200285T1/en unknown
-
2021
- 2021-10-11 US US17/450,465 patent/US11918639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265733B (en) | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection | |
| EP2969770A4 (en) | Impact protection apparatus | |
| HK1219577A1 (en) | Surge protective system | |
| ZA201701815B (en) | Methods and compositions for inducing protective immunity against filovirus infection | |
| GB201403533D0 (en) | Protection device | |
| IL248877A0 (en) | Compositions and methods for enhancing immunity | |
| PL3042697T3 (en) | Protective suit | |
| PL2991177T3 (en) | Overvoltage protection device | |
| EP3018518A4 (en) | Protection member | |
| GB201400863D0 (en) | Protection device | |
| HK1222592A1 (en) | Hand protection device | |
| GB201512007D0 (en) | Protective device | |
| ZA201505557B (en) | Protective arrangement | |
| AP2015008350A0 (en) | Protective garment | |
| GB201413176D0 (en) | Protection device | |
| GB201407363D0 (en) | Inflatable protection suit | |
| AP00866S1 (en) | Protective garment |